Search

Displaying results 5791 - 5800 of 8196 in total
  1. Drug

    OptPA

    go.drugbank.com/drugs/DB18325
    Experimental

    Optimized tPA (OptPA; W253R/R275S-tPA) is an engineered variant of tPA designed to exhibit reduced neurotoxicity.[A261486]

  2. Drug

    DengueCide

    go.drugbank.com/drugs/DB18546
    Experimental

    DengueCide is a nonjugate of a dengue virus specific small chemical ligand and an amphiphilic PEG based polymer

  3. Drug

    Pexelizumab

    go.drugbank.com/drugs/DB04949
    Investigational

    Pexelizumab is a humanized monoclonal antibody used as an immunosuppressive drug. It is being investigated by Alexion Pharmaceuticals.

  4. Drug

    Zibrofusidic acid

    go.drugbank.com/drugs/DB20799
    Investigational

    Zibrofusidic acid has a monoisotopic molecular weight of 594.26 Da.

  5. Drug

    Evixapodlin

    go.drugbank.com/drugs/DB21520
    Investigational

    Evixapodlin has a monoisotopic molecular weight of 690.22 Da.

  6. Drug

    Lexanersen

    go.drugbank.com/drugs/DB17933
    Investigational

    Lexanersen is an antisense oligonucleotide under investigation for use as a disease-modifying therapy in Huntington's disease.

    Synonyms: Dna, d(rgm-(p(s))-sp-rum-rgm-rcm-ram-(p(s))-sp-c-(p(s))-sp-a-(p(s))-sp-c-(p(s))-sp-a-(p(s))-sp-g-(p(s))-sp-t-(p(s))-sp-a-(p(s))-sp-g-(p(r))-sp-a-(p(s))-sp-t-(p(s))-sp-rgm-ram-rgm-rgm-(p(s))-sp-rgm)
  7. Drug

    BD-111

    go.drugbank.com/drugs/DB18247
    Investigational

    BD-111 is an HSV-1-erasing lentivirus-like particle delivering gRNA-expressing cassette and SpCas9 mRNA.

  8. Drug

    HSV-2 theracine

    go.drugbank.com/drugs/DB05811
    Experimental

    HSV-2 theracine is an attenuated recombinant vaccine developed by AuRx for the treatment of genital herpes.

  9. Drug

    ADC4022

    go.drugbank.com/drugs/DB05195
    Investigational

    ADC4022 is an investigational medicine for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and severe asthma.

  10. Drug

    RTN-001

    go.drugbank.com/drugs/DB05615
    Investigational

    SLx-2101 is an oral, long-acting PDE5 inhibitor developed by Surface Logix Inc. to treat Hypertension.